Automated CAR T cell manufacturing

Learn more about the CliniMACS Prodigy https://www.miltenyibiotec.com/products/cell-manufacturing-platform/clinimacs-prodigy.html With the CliniMACS Prodigy® T Cell Transduction Process you can now manufacture CAR T cells in a simple and fully automated fashion. The CliniMACS Prodigy® is able to perform cell enrichment, activation, genetic manipulation, and expansion with minimal involvement from the user. All steps take place in a closed system, providing a sterile solution for the challenges associated with clinical-grade CAR T cell production. All reagents for cell enrichment and activation as well as cytokines and media are available in MACS® GMP quality.

The advantages of the CliniMACS Prodigy for the clinical-scale production of CAR T cells:

• automated CAR T cell production
• minimal hands-on-time from the operator
• sterile expansion in a single-use closed system
• supports both local and large scale production of CAR T cells
• standardized process for robust and consistent results

Learn more about the advantages of our automated CAR T cell manufacturing process https://www.miltenyibiotec.com/applications/t-cells/gmp-engineered-t-cells.html
Learn more about the CliniMACS Prodigy https://www.miltenyibiotec.com/products/cell-manufacturing-platform/clinimacs-prodigy.html
Understand how the CliniMACS Prodigy works https://www.miltenyibiotec.com/products/cell-manufacturing-platform/clinimacs-prodigy/CliniMACS-Prodigy-principle.html

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. The company is committed to enable commercial scale cell and gene therapy for the delivery of new treatment options to patients with unmet medical need. The company’s state-of-the-art technologies and products provide integrated workflows for research and clinical applications and have set a new industry standard in automated manufacturing of complex cellular products such as CAR T cells, TCR-transduced T cells, and gene-modified stem cells. Miltenyi Biotec’s portfolio of instruments, reagents and disposables is complemented with contract development and cGMP manufacturing services for lentiviral vectors and cellular products based on the company’s unique platforms for cell processing and cellular analytics. Miltenyi Biotec has more than 2,500 employees in 28 countries and its products have been used in more than 50,000 cell therapy procedures. For more information please visit www.miltenyibiotec.com

Видео Automated CAR T cell manufacturing канала Miltenyi Biotec